ABNX ABIONYX Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of sepsis. It is also developing ABNX-100, a strategic extension into ophthalmology of CER-001 that is in preclinical trial for the treatment of uveitis. ABIONYX Pharma SA has a strategic partnership with Lille University Hospitalburn treatment center and intensive care unit to explore the potential of CER-001 in severe burn patients at high risk for sepsis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was incorporated in 2005 and is headquartered in Balma, France.…
Industry Peers
BiotechnologyKey Statistics
About ABIONYX Pharma (EPA: ABNX)
›
ABIONYX Pharma (EPA: ABNX) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 49 employees.
The shares were at 1.542 EUR on 19 November 2026, down 63.2% over 52 weeks. Its 52-week range is 1.414 EUR to 4.400 EUR: the price is 65.0% below the high and 9.1% above the low.
Its market capitalisation is 68.78M EUR.
ABIONYX Pharma reports return on equity of -123.0%, an operating margin of -136.3% and revenue down 11.9% year over year.
Its debt exceeds its cash by 284.00K EUR, a debt-to-equity ratio of 0.84. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.